The new CE-IVD registered BD MAX™ Check-Points CPO assay is the latest addition to a portfolio of screening assays for rapid AMR detection on the automated BD MAX™ System. The other Check-Points assay in this portfolio is the Check-Direct ESBL Screen for BD MAX™ detecting ESBLs. Becton Dickinson (BD) markets assays on MRSA, VRE and CDiff for the BD MAX™.

The BD MAX™ Check-Points CPO assay detects the five worldwide most prevalent carbapenemase genes (KPC, OXA-48 like, NDM, VIM and IMP) directly from rectal swabs, in under 2.5 hours turnaround time, and at high sensitivity and specificity compared to traditional plated media methods.

Active molecular screening of high-risk potential CPO carriers allows for faster and more accurate decisions on the isolation or de-isolation of patients, thereby reducing the risk of CPO transmission and outbreaks, plus a reduction in pre-emptive isolation days.

Like to talk to us about CPO, AMR or fast and accurate molecular detection? Come and visit us at booth #20B at ECCMID 2018.

For more information visit www.check-points.com.